Invention Grant
- Patent Title: TRPA1 antagonists
- Patent Title (中): TRPA1拮抗剂
-
Application No.: US13499844Application Date: 2010-09-28
-
Publication No.: US08829196B2Publication Date: 2014-09-09
- Inventor: Mark T. Bilodeau , Melissa Egbertson , Ahren Green , John C. Hartnett , Yiwei Li
- Applicant: Mark T. Bilodeau , Melissa Egbertson , Ahren Green , John C. Hartnett , Yiwei Li
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; John C. Todaro
- International Application: PCT/US2010/050493 WO 20100928
- International Announcement: WO2011/043954 WO 20110414
- Main IPC: C07D215/38
- IPC: C07D215/38 ; C07C215/20 ; C07C211/34 ; C07C25/02 ; A61K31/133

Abstract:
The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function. The present invention further relates to methods and compositions that antagonize both a function of TRPA1 and a function of one or more additional TRP channels.
Public/Granted literature
- US20120196894A1 NOVEL TRPA1 ANTAGONISTS Public/Granted day:2012-08-02
Information query